Breaking News

ANI Pharma Expands Sofgen Development Pact

May 1, 2014

Sofgen to develop, manufacture generic soft gel drug product

ANI Pharmaceuticals, Inc. has signed an exclusive licensing, development and supply agreement with Sofgen Pharmaceuticals for an undisclosed ANDA soft gel oral drug product. Sofgen will provide development, manufacture and regulatory submission of the drug, and ANI will be responsible for marketing and distribution in the U.S.
 
The branded product had annual U.S. sales of approximately $1 billion, according to IMS Health. Financial terms were not disclosed.
 
Arthur S. Przybyl, ANI's president and chief executive officer, said, "I am pleased to have expanded our collaboration with Sofgen through the addition of this second generic drug development project. ANI will continue to invest in both internal R&D efforts as well as external partnerships with high quality partners such as Sofgen."

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016